Skip to main content
logo
Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
2.510
-0.090 (-3.46%)
Oct 26, 2026, 10:20 AM EDT - Market open

Atossa Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
------
Revenue Growth
------
Gross Profit
------
Operating Income
-39.25-37.14-27.62-31.38-27.69-20.52
Net Income
-37.71-34.77-25.5-30.09-26.96-20.61
Earnings Per Share
-4.34-4.04-3.04-3.58-3.19-2.64
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
26.0941.371.0888.46110.89136.38
Total Debt
------
Net Cash (Debt)
26.0941.371.0888.46110.89136.38
Net Cash Growth
-54.90%-41.90%-19.64%-20.23%-18.69%244.94%
Net Cash Per Share
3.014.808.4710.5213.1417.49

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-35.77-29.76-21.03-20.94-20.76-16.47
Capital Expenditures
-0.01-0.02-0.02-0.01-0.03-0.01
Free Cash Flow
-35.78-29.79-21.05-20.96-20.79-16.48
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Margin
------
Profit Margin
------
FCF Margin
------

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-181.67181.67181.67181.67181.67
PS Ratio
------